Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Cohen

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Cancer Research Communications|March 27, 2023
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)Aaron J Scott, Atrayee Basu Mallick, Efrat Dotan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2007
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinomaAndre A Konski, Jonathan D Cheng, Melvyn Goldberg, et al.
Investigational New Drugs|July 25, 2019
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancerS Lindsey Davis, Dana B Cardin, Safi Shahda, et al.
American Journal of Clinical Oncology|May 12, 2010
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinomaIgor A Astsaturov, Neal J Meropol, R Katherine Alpaugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trialSeza A Gulec, Steven J Cohen, Kenneth L Pennington, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 12, 2012
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancerAndre Konski, Tianyu Li, Michael Christensen, et al.
Pancreas|March 12, 2016
Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic AdenocarcinomaEfrat Dotan, R Katherine Alpaugh, Karen Ruth, et al.
The Oncologist|April 27, 2023
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN TrialShannon Stockton, Paul Catalano, Steven J Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 4, 2014
Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutionsMarsha Reyngold, Joyce Niland, Anna ter Veer, et al.
Clinical Colorectal Cancer|February 12, 2014
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancersCrystal S Denlinger, Neal J Meropol, Tianyu Li, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Cancer Research Communications|March 27, 2023
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)Aaron J Scott, Atrayee Basu Mallick, Efrat Dotan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2007
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinomaAndre A Konski, Jonathan D Cheng, Melvyn Goldberg, et al.
Investigational New Drugs|July 25, 2019
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancerS Lindsey Davis, Dana B Cardin, Safi Shahda, et al.
American Journal of Clinical Oncology|May 12, 2010
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinomaIgor A Astsaturov, Neal J Meropol, R Katherine Alpaugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2011
Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trialSeza A Gulec, Steven J Cohen, Kenneth L Pennington, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 12, 2012
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancerAndre Konski, Tianyu Li, Michael Christensen, et al.
Pancreas|March 12, 2016
Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic AdenocarcinomaEfrat Dotan, R Katherine Alpaugh, Karen Ruth, et al.
The Oncologist|April 27, 2023
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN TrialShannon Stockton, Paul Catalano, Steven J Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 4, 2014
Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutionsMarsha Reyngold, Joyce Niland, Anna ter Veer, et al.
Clinical Colorectal Cancer|February 12, 2014
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancersCrystal S Denlinger, Neal J Meropol, Tianyu Li, et al.
Pageof 11